Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative

Cancer Letters

Volumn 132, Issue 1-2, 1998, Pages 45-50

  Mendez Vidal C ^a   Quesada, A R ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Ardeemin; Multidrug resistance; Resistance modifier agent; Rhodamine 123; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; AV 200; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; RHODAMINE 123; TUMOR CELLS, CULTURED; VERAPAMIL; VINCRISTINE;

EID: 0032561286     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00156-6     Document Type: Article

References (26)

1. Beck W.T., Qian X.D. Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol. 43:1992;89-93.
2. Chan H.S.L., Grogan T.M., DeBoer G., Haddad G., Gallie B.L., Ling V. Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur. J. Cancer. 32A:1996;1051-1061.
3. Conforti G., Codegoni A.M., Scanziani E., Dolfini E., Dasdia T., Calza M., Caniatti M., Broggini M. Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Br. J. Cancer. 71:1995;505-511.
4. Ferry D.R., Traunecker H., Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer. 32A:1996;1070-1081.
5. Germann U.A. P-Glycoprotein. A mediator of multidrug resistance in tumour cells. Eur. J. Cancer. 32A:1996;927-944.
6. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
7. Grandi M., Young C., Bellini O., Geri O., Muindi J., Giuliani F. Pleiotropic multidrug resistant LoVo, P388 and I-407 cell lines have an increased tubulovesicular compartment. Proc. Am. Assoc. Cancer Res. 28:1987;279.
8. Grandi M., Geroni C., Giuliani F.C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br. J. Cancer. 54:1986;515-518.
9. Jachez B., Nordmann R., Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst. 85:1993;478-483.
10. Keller R.P., Altermatt H.J., Nooter K., Poschmann G., Laissue J.A., Bollinger P., Hiestand P.C. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer. 50:1992;593-597.
11. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer. 32A:1996;912-920.
12. Loor F., Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Emmer G. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein mediated tumour cell multidrug resistance. Br. J. Cancer. 65:1992;11-18.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
14. Ozols R.F., Cunnion R.E., Kleker R.W., Hamilton T.C., Ostchega Y., Parillo J.E., Young R.C. Verapamil and doxorubicin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:1987;641-647.
15. Patel N.H., Rothenberg M.L. Multidrug resistance in cancer chemotherapy. Invest. New Drug. 12:1994;1-13.
16. Pearce H.L., Safa A.R., Bach N.J., Winter M.A., Cirtain M.C., Beck W.T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA. 86:1989;5128-5132.
17. Pennock G.D., Dalton W.S., Roeske W.R., Appleton C.P., Mosley K., Plezia P., Miller T.P., Salmon S.E. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst. 83:1991;105-110.
18. Pilarsky L.M., Belch A.J. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood. 83:1994;124-136.
19. Quesada A.R., Barbacid M.M., Mira E., Aracil M., Márquez G. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Cancer Lett. 99:1996;109-114.
20. Quesada A.R., García Grávalos M.D., Fernández Puentes J.L. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. Br. J. Cancer. 74:1996;677-682.
21. Rasola A., Galietta L.J., Gruenert D.C., Romeo G. Volume-sensitive chloride currents in four epithelial cell lines are not directly correlated to the expression of the MDR-1 gene. J. Biol. Chem. 269:1994;1432-1436.
22. Sonneveld P. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur. J. Cancer. 32A:1996;1062-1069.
23. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
24. Twentyman P.R., Bleehen N.M. Resistance modification by PSC-833: a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer. 27:1991;1639-1642.
25. Twentyman P.R., Rhodes T., Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotype. Eur. J. Cancer. 30A:1994;1360-1369.
26. Zamora J.M., Pearce H.L., Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:1988;454-462.